Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.
May 17 2019 - 9:24AM
Jamieson Bondarenko (“
Bondarenko”) announced today
that he has acquired an aggregate of 1,698,000 common shares (the
“
Shares”) of BriaCell Therapeutics Corp.
(BCT-TSXV) (“
BriaCell”). Bondarenko acquired the
Shares through the facilities of the TSX Venture Exchange at an
average purchase price of $0.083 per Share for an aggregate
purchase price of $140,575 (the “
Acquisition”) as
disclosed on SEDI.ca.
Prior to the Acquisition, Bondarenko previously
reported holding 26,745,500 common shares of BriaCell, representing
approximately 13.5% of BriaCell’s issued and outstanding common
shares. As a result of the Acquisition of the Shares,
Bondarenko now has beneficial ownership of an aggregate of
28,443,500 common shares, representing approximately 14.48% of
BriaCell’s issued and outstanding common shares.
Bondarenko has acquired these securities for
investment purposes and may increase or decrease his beneficial
ownership or control over securities of BriaCell as circumstances
or market conditions warrant.
This news release is issued pursuant to National
Instrument 62-103, The Early Warning System and Related Take-Over
Bid and Insider Reporting Issues. A copy of the early warning
report will appear with BriaCell’s documents on the System for
Electronic Document Analysis and Retrieval at www.sedar.com.
BriaCell‘s head office is located at 3rd Floor,
Bellevue Centre, 235-15th Street, West Vancouver, British Columbia
V7T 2X1.
For further information or to request a copy of
the early warning report, please contact:
Jamieson Bondarenko 416-427-7998
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2024 to May 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From May 2023 to May 2024